by Options Weight Loss | Dec 7, 2023 | Articles, Health, Weight Loss
Are you struggling with weight loss while dealing PCOS? You’re not alone. Polycystic ovary syndrome (PCOS) affects millions of women worldwide, causing a range of symptoms that can make losing weight seem like an uphill battle. Up to 15% women of reproductive...
by Options Weight Loss | Dec 1, 2023 | Articles, Health, Weight Loss
The holiday season is chock full of gatherings big and small. Between family celebrations, office parties, and gatherings with friends there is no shortage of opportunities to over-indulge. While going astray of your weight management may be a temptation, follow our...
by Options Weight Loss | Nov 22, 2023 | Articles, Health, Weight Loss, Weight Loss Medication
Semaglutide, a GLP-1 medication, is taking the weight loss world by storm. Several GLP-1 medications are now on the market including semaglutide, Wegovy®, Ozempic®, Rybelsus®, Saxenda®, Victoza®, Trulicity®, Zepbound™and Mounjaro® (Tirzepatide). If you’re taking...
by Options Weight Loss | Nov 17, 2023 | Articles, Health, Weight Loss, Weight Loss Medication
Another breakthrough in the fight against obesity! The Food and Drug Administration (FDA) has recently approved Eli Lilly’s Zepbound™ (Tirzepatide), a groundbreaking medication designed to tackle the challenges of obesity. Studies showed patients losing up to...
by Options Weight Loss | Nov 14, 2023 | Articles, Health, Weight Loss
Thanksgiving Day in America centers around gratitude. A ‘feast’ or large meal is a quintessential part of Thanksgiving Day for many people to celebrate things they’re thankful for. Wherever you are in your weight loss journey, a Thanksgiving meal and...
by Options Weight Loss | Nov 3, 2023 | Articles, Health, Weight Loss, Weight Loss Medication
When it comes to weight loss medications, Ozempic® , Wegovy® and semaglutide are names that often pop up in discussions. They are all associated with impressive weight loss results, but what exactly sets them apart? In this comprehensive comparison, we’ll...